Susan Arentz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Susan Arentz has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Anne Smith
NICM Health Research Institute, Western Sydney University, Penrith, Australia
6 shared publications - Jennifer Hunter
Health Research Group Pty. Limited, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Australia
6 shared publications - Joshua Goldenberg
Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, USA
5 shared publications - Alan Bensoussan
NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia
4 shared publications - Guoyan Yang
NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia
4 shared publications - Jason Abbott
National Endometriosis Clinical and Scientific Trials (NECST) Network, UNSW Sydney
4 shared publications
Latest Publications
- Open Access
Perceptions of Open Science in the Editorial and Peer Review Process: A Cross-Sectional Survey of Traditional, Complementary, and Integrative Medicine Journal Editors
Background: Open science (OS) offers opportunities to address challenges in the editorial and peer review processes of traditional, complementary, and integrative medicine (TCIM) journals. This study assessed TCIM journal editors’ perceptions of OS and the perceived benefits and challenges of integrating OS into editorial and peer review processes. Methods: A cross-sectional survey was distributed to editors-in-chief, associate editors, and editorial board members of 115 TCIM journals. The survey examined demographics, current use and familiarity with OS, perceived advantages and obstacles, and future perspectives on OS in academic publishing. Quantitative data were analyzed descriptively, and qualitative data were examined using thematic analysis. Results: A total of 267 respondents completed the survey, with most identifying as faculty members or academic research staff (n = 201/335, 60.0%). Most respondents were familiar (n = 128/212, 60.3%) or very familiar (n = 64/212, 30.2%) with OS practices, although many had received no formal OS training (n = 94/210, 44.8%). Respondents were most familiar with open access (n = 131/213, 61.5%) and preprints (n = 92/211, 43.6%). Among the seven OS practices examined, open access was viewed most favorably, with many considering it "very important" (n = 97/206, 47.1%) and strongly agreeing that it enhances the accessibility of research findings (n = 118/195, 60.5%). Conclusion: Most respondents were familiar with OS but held varying perceptions regarding the importance, advantages, and disadvantages of different OS practices. These findings may inform the development and implementation of evidence-based practices and policies that meet the needs of the TCIM research community.
Open AccessPerceptions of Open Science in the Editorial and Peer Review Process: A Cross-Sectional Survey of Traditional, Complementary, and Integrative Medicine Journal Editors
Background: Open science (OS) offers opportunities to address challenges in the editorial and peer review processes of traditional, complementary, and integrative medicine (TCIM) journals. This study assessed TCIM journal editors’ perceptions of OS and the perceived benefits and challenges of integrating OS into editorial and peer review processes. Methods: A cross-sectional survey was distributed to editors-in-chief, associate editors, and editorial board members of 115 TCIM journals. The survey examined demographics, current use and familiarity with OS, perceived advantages and obstacles, and future perspectives on OS in academic publishing. Quantitative data were analyzed descriptively, and qualitative data were examined using thematic analysis. Results: A total of 267 respondents completed the survey, with most identifying as faculty members or academic research staff (n = 201/335, 60.0%). Most respondents were familiar (n = 128/212, 60.3%) or very familiar (n = 64/212, 30.2%) with OS practices, although many had received no formal OS training (n = 94/210, 44.8%). Respondents were most familiar with open access (n = 131/213, 61.5%) and preprints (n = 92/211, 43.6%). Among the seven OS practices examined, open access was viewed most favorably, with many considering it "very important" (n = 97/206, 47.1%) and strongly agreeing that it enhances the accessibility of research findings (n = 118/195, 60.5%). Conclusion: Most respondents were familiar with OS but held varying perceptions regarding the importance, advantages, and disadvantages of different OS practices. These findings may inform the development and implementation of evidence-based practices and policies that meet the needs of the TCIM research community.
- Open Access
- 8 August 2025
- Published by Elsevier in Integrative Medicine Research
- Vol. 14 (4) , 101220
Improving evidence synthesis: Clarifying explanatory and effectiveness randomized clinical trials in complementary and integrative medicine
- 8 August 2025
- Published by Elsevier in Integrative Medicine Research
- Vol. 14 (4) , 101220
Open AccessImproving evidence synthesis: Clarifying explanatory and effectiveness randomized clinical trials in complementary and integrative medicine
- 8 November 2024
- Published by Elsevier in Advances in Integrative Medicine
- Vol. 11 (4) , 183
Editorial: Indigenous medicine—A wisdom of balance and belonging
- 8 November 2024
- Published by Elsevier in Advances in Integrative Medicine
- Vol. 11 (4) , 183
Editorial: Indigenous medicine—A wisdom of balance and belonging
- 14 August 2024
- Published by Elsevier in Advances in Integrative Medicine
- Vol. 11 (3) , 121-122
Integrative medicine healthcare, research and education
- 14 August 2024
- Published by Elsevier in Advances in Integrative Medicine
- Vol. 11 (3) , 121-122
Integrative medicine healthcare, research and education
- Open Access
- 21 March 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (4) , 390-398
Health needs, treatment decisions and experience of traditional complementary and integrative medicine use by women with diminished ovarian reserve: A cross‐sectional survey
Background: Women with diminished ovarian reserve (DOR) have fewer eggs than would be expected at their age. It is estimated that 10% of women seeking fertility treatment are diagnosed with DOR. However, the success rate of medically assisted reproduction (MAR) is significantly lower in women with DOR, thus many seek additional approaches.Aim: To explore the health needs of women with DOR, treatment options and experience of treatment including traditional complementary integrative medicine (TCIM).Methods: Anyone with a diagnosis of DOR, living in Australia or New Zealand, aged over 18 were invited to complete an online survey distributed via fertility support networks and social media platforms from April to December 2021.Results: Data from 67 respondents were included. The main aspects of health that were impacted by DOR were fertility (91.0%) and mental health (52.2%). The main treatment recommended was MAR with most women either currently using MAR (38.8%) or having previously used MAR (37.3%). TCIM was widely used with 88.1% of women utilising supplements, 74.6% consulting with TCIM practitioners, and 65.7% adopting self‐care practices. The main reasons for using TCIM were to improve fertility or support pregnancy, and to support general health and well‐being.Conclusions: Women with DOR have additional health needs apart from infertility, most notably mental health support. The main form of treatment utilised is MAR, despite DOR being challenging for fertility clinicians. TCIM was widely used, and respondents perceived benefits related to improving fertility, supporting pregnancy, or improving well‐being through use of acupuncture, meditation, naturopathy, massage, yoga.
- 21 March 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (4) , 390-398
Open AccessHealth needs, treatment decisions and experience of traditional complementary and integrative medicine use by women with diminished ovarian reserve: A cross‐sectional survey
Background: Women with diminished ovarian reserve (DOR) have fewer eggs than would be expected at their age. It is estimated that 10% of women seeking fertility treatment are diagnosed with DOR. However, the success rate of medically assisted reproduction (MAR) is significantly lower in women with DOR, thus many seek additional approaches.Aim: To explore the health needs of women with DOR, treatment options and experience of treatment including traditional complementary integrative medicine (TCIM).Methods: Anyone with a diagnosis of DOR, living in Australia or New Zealand, aged over 18 were invited to complete an online survey distributed via fertility support networks and social media platforms from April to December 2021.Results: Data from 67 respondents were included. The main aspects of health that were impacted by DOR were fertility (91.0%) and mental health (52.2%). The main treatment recommended was MAR with most women either currently using MAR (38.8%) or having previously used MAR (37.3%). TCIM was widely used with 88.1% of women utilising supplements, 74.6% consulting with TCIM practitioners, and 65.7% adopting self‐care practices. The main reasons for using TCIM were to improve fertility or support pregnancy, and to support general health and well‐being.Conclusions: Women with DOR have additional health needs apart from infertility, most notably mental health support. The main form of treatment utilised is MAR, despite DOR being challenging for fertility clinicians. TCIM was widely used, and respondents perceived benefits related to improving fertility, supporting pregnancy, or improving well‐being through use of acupuncture, meditation, naturopathy, massage, yoga.
- 1 July 2022
- Published by Elsevier in Women and Birth
- Vol. 35 (4) , e303-e317
Complementary medicines and therapies in clinical guidelines on pregnancy care: A systematic review
- 1 July 2022
- Published by Elsevier in Women and Birth
- Vol. 35 (4) , e303-e317
Complementary medicines and therapies in clinical guidelines on pregnancy care: A systematic review
- 1 December 2021
- Published by Elsevier in European Journal of Integrative Medicine
- Vol. 48, 101941
Women's Chronic Pelvic Pain: Traditional Chinese Medicine practitioners knowledge and integration
- 1 December 2021
- Published by Elsevier in European Journal of Integrative Medicine
- Vol. 48, 101941
Women's Chronic Pelvic Pain: Traditional Chinese Medicine practitioners knowledge and integration
- 1 December 2021
- Published by Elsevier in European Journal of Integrative Medicine
- Vol. 48, 101909
Integrating complementary medicine into a clinical guideline for diabetes palliative care.
- 1 December 2021
- Published by Elsevier in European Journal of Integrative Medicine
- Vol. 48, 101909
Integrating complementary medicine into a clinical guideline for diabetes palliative care.
- Open Access
Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials
Objective To evaluate the benefits and risks of zinc formulations compared with controls for prevention or treatment of acute viral respiratory tract infections (RTIs) in adults. Method Seventeen English and Chinese databases were searched in April/May 2020 for randomised controlled trials (RCTs), and from April/May 2020 to August 2020 for SARS-CoV-2 RCTs. Cochrane rapid review methods were applied. Quality appraisals used the Risk of Bias 2.0 and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Results Twenty-eight RCTs with 5446 participants were identified. None were specific to SARS-CoV-2. Compared with placebo, oral or intranasal zinc prevented 5 RTIs per 100 person-months (95% CI 1 to 8, numbers needed to treat (NNT)=20, moderate-certainty/quality). Sublingual zinc did not prevent clinical colds following human rhinovirus inoculations (relative risk, RR 0.96, 95% CI 0.77 to 1.21, moderate-certainty/quality). On average, symptoms resolved 2 days earlier with sublingual or intranasal zinc compared with placebo (95% CI 0.61 to 3.50, very low-certainty/quality) and 19 more adults per 100 were likely to remain symptomatic on day 7 without zinc (95% CI 2 to 38, NNT=5, low-certainty/quality). There were clinically significant reductions in day 3 symptom severity scores (mean difference, MD −1.20 points, 95% CI −0.66 to −1.74, low-certainty/quality), but not average daily symptom severity scores (standardised MD −0.15, 95% CI −0.43 to 0.13, low-certainty/quality). Non-serious adverse events (AEs) (eg, nausea, mouth/nasal irritation) were higher (RR 1.41, 95% CI 1.17 to 1.69, NNHarm=7, moderate-certainty/quality). Compared with active controls, there were no differences in illness duration or AEs (low-certainty/quality). No serious AEs were reported in the 25 RCTs that monitored them (low-certainty/quality). Conclusions In adult populations unlikely to be zinc deficient, there was some evidence suggesting zinc might prevent RTIs symptoms and shorten duration. Non-serious AEs may limit tolerability for some. The comparative efficacy/effectiveness of different zinc formulations and doses were unclear. The GRADE-certainty/quality of the evidence was limited by a high risk of bias, small sample sizes and/or heterogeneity. Further research, including SARS-CoV-2 clinical trials is warranted. PROSPERO registration number CRD42020182044.
Open AccessZinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials
Objective To evaluate the benefits and risks of zinc formulations compared with controls for prevention or treatment of acute viral respiratory tract infections (RTIs) in adults. Method Seventeen English and Chinese databases were searched in April/May 2020 for randomised controlled trials (RCTs), and from April/May 2020 to August 2020 for SARS-CoV-2 RCTs. Cochrane rapid review methods were applied. Quality appraisals used the Risk of Bias 2.0 and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Results Twenty-eight RCTs with 5446 participants were identified. None were specific to SARS-CoV-2. Compared with placebo, oral or intranasal zinc prevented 5 RTIs per 100 person-months (95% CI 1 to 8, numbers needed to treat (NNT)=20, moderate-certainty/quality). Sublingual zinc did not prevent clinical colds following human rhinovirus inoculations (relative risk, RR 0.96, 95% CI 0.77 to 1.21, moderate-certainty/quality). On average, symptoms resolved 2 days earlier with sublingual or intranasal zinc compared with placebo (95% CI 0.61 to 3.50, very low-certainty/quality) and 19 more adults per 100 were likely to remain symptomatic on day 7 without zinc (95% CI 2 to 38, NNT=5, low-certainty/quality). There were clinically significant reductions in day 3 symptom severity scores (mean difference, MD −1.20 points, 95% CI −0.66 to −1.74, low-certainty/quality), but not average daily symptom severity scores (standardised MD −0.15, 95% CI −0.43 to 0.13, low-certainty/quality). Non-serious adverse events (AEs) (eg, nausea, mouth/nasal irritation) were higher (RR 1.41, 95% CI 1.17 to 1.69, NNHarm=7, moderate-certainty/quality). Compared with active controls, there were no differences in illness duration or AEs (low-certainty/quality). No serious AEs were reported in the 25 RCTs that monitored them (low-certainty/quality). Conclusions In adult populations unlikely to be zinc deficient, there was some evidence suggesting zinc might prevent RTIs symptoms and shorten duration. Non-serious AEs may limit tolerability for some. The comparative efficacy/effectiveness of different zinc formulations and doses were unclear. The GRADE-certainty/quality of the evidence was limited by a high risk of bias, small sample sizes and/or heterogeneity. Further research, including SARS-CoV-2 clinical trials is warranted. PROSPERO registration number CRD42020182044.
- Open Access
- 1 October 2021
- Published by Elsevier in Integrative Medicine Research
- Vol. 10 (Suppl) , 100779
Honeybee products for the treatment and recovery from viral respiratory infections including SARS-CoV-2: A rapid systematic review
- 1 October 2021
- Published by Elsevier in Integrative Medicine Research
- Vol. 10 (Suppl) , 100779
Open AccessHoneybee products for the treatment and recovery from viral respiratory infections including SARS-CoV-2: A rapid systematic review